667 related articles for article (PubMed ID: 30677473)
21. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
22. Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice.
Vizirianakis IS
Curr Drug Deliv; 2004 Jan; 1(1):73-80. PubMed ID: 16305372
[TBL] [Abstract][Full Text] [Related]
23. Pharmacoepigenetics: an element of personalized therapy?
Majchrzak-Celińska A; Baer-Dubowska W
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):387-398. PubMed ID: 27860490
[TBL] [Abstract][Full Text] [Related]
24. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions.
Pirmohamed M
Annu Rev Genomics Hum Genet; 2014; 15():349-70. PubMed ID: 24898040
[TBL] [Abstract][Full Text] [Related]
25. Towards pharmacogenomics knowledge discovery with the semantic web.
Dumontier M; Villanueva-Rosales N
Brief Bioinform; 2009 Mar; 10(2):153-63. PubMed ID: 19240125
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics of adverse drug reactions: implementing personalized medicine.
Wei CY; Lee MT; Chen YT
Hum Mol Genet; 2012 Oct; 21(R1):R58-65. PubMed ID: 22907657
[TBL] [Abstract][Full Text] [Related]
27. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
[TBL] [Abstract][Full Text] [Related]
28. Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.
La Russa R; Fineschi V; Di Sanzo M; Gatto V; Santurro A; Martini G; Scopetti M; Frati P
Curr Pharm Biotechnol; 2017; 18(3):274-281. PubMed ID: 28176638
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomic biomarkers: new tools in current and future drug therapy.
Sim SC; Ingelman-Sundberg M
Trends Pharmacol Sci; 2011 Feb; 32(2):72-81. PubMed ID: 21185092
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
[TBL] [Abstract][Full Text] [Related]
31. Report on the pharmacogenomics and personalized medicine 2011 conference: part 1.
Harrison N
Pharmacogenomics; 2012 Jan; 13(2):141-5. PubMed ID: 22256866
[TBL] [Abstract][Full Text] [Related]
32. Reducing false positive findings in statistical analysis of pharmacogenomic biomarker studies using high-throughput technologies.
Matsui S
Curr Drug Saf; 2006 May; 1(2):135-41. PubMed ID: 18690924
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics discovery and implementation in genome-wide association studies era.
Ni X; Zhang W; Huang RS
Wiley Interdiscip Rev Syst Biol Med; 2013; 5(1):1-9. PubMed ID: 23188748
[TBL] [Abstract][Full Text] [Related]
34. Modern developments in germline pharmacogenomics for oncology prescribing.
Reizine NM; O'Donnell PH
CA Cancer J Clin; 2022 Jul; 72(4):315-332. PubMed ID: 35302652
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies.
Samwald M; Miñarro Giménez JA; Boyce RD; Freimuth RR; Adlassnig KP; Dumontier M
BMC Med Inform Decis Mak; 2015 Feb; 15():12. PubMed ID: 25880555
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenomic biomarkers.
Kirkwood SC; Hockett RD
Dis Markers; 2002; 18(2):63-71. PubMed ID: 12364812
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.
Sleder AT; Kalus J; Lanfear DE
J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):20-6. PubMed ID: 26054891
[TBL] [Abstract][Full Text] [Related]
38. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.
Arbitrio M; Di Martino MT; Scionti F; Agapito G; Guzzi PH; Cannataro M; Tassone P; Tagliaferri P
Oncotarget; 2016 Aug; 7(33):54028-54050. PubMed ID: 27304055
[TBL] [Abstract][Full Text] [Related]
39. Translating pharmacogenomic sequencing data into drug response predictions-How to interpret variants of unknown significance.
Tremmel R; Pirmann S; Zhou Y; Lauschke VM
Br J Clin Pharmacol; 2023 Sep; ():. PubMed ID: 37759374
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetic Markers of Drug Efficacy and Toxicity.
Yip VL; Hawcutt DB; Pirmohamed M
Clin Pharmacol Ther; 2015 Jul; 98(1):61-70. PubMed ID: 25870137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
